Journal
MOLECULES
Volume 26, Issue 13, Pages -Publisher
MDPI
DOI: 10.3390/molecules26134100
Keywords
mammalian target of rapamycin (mTOR); natural compounds; protein kinase B (PKB; AKT); phosphatidylinositol-3-kinase (PI3K)
Funding
- Second Century Fund
- Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University
Ask authors/readers for more resources
Lung cancer is a common and highly lethal cancer, posing a major clinical challenge. The PI3K/AKT/mTOR pathway has been linked to lung cancer, making it a significant therapeutic target. Interest in targeting these pathways with medications has grown, showing promise in various types of studies.
Lung cancer is one of the most common cancers and has a high mortality rate. Due to its high incidence, the clinical management of the disease remains a major challenge. Several reports have documented a relationship between the phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathway and lung cancer. The recognition of this pathway as a notable therapeutic target in lung cancer is mainly due to its central involvement in the initiation and progression of the disease. Interest in using natural and synthetic medications to target these signaling pathways has increased in recent years, with promising results in vitro, in vivo, and in clinical trials. In this review, we focus on the current understanding of PI3K/AKT/mTOR signaling in tumor development. In addition to the signaling pathway, we highlighted the therapeutic potential of recently developed PI3K/AKT/mTOR inhibitors based on preclinical and clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available